PROVECTUS BIOPHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $20.55M
- P/E (TTM)
- –
- Dividend yield
- –
About Provectus Biopharmaceuticals
Pharmaceutical Preparations, SIC 2834
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company that develops immunotherapy medicines for various diseases. The company's drug candidates utilize bioactive, synthetic, pharmaceutical-grade rose bengal sodium, a small molecule within the halogenated xanthenes class. Its clinical programs focus on oncology via intratumoral administration, dermatology through topical formulations, and ophthalmology. Primary investigational candidates include PV-10 for cancer indications such as melanoma and liver cancers, and PH-10 for skin conditions like psoriasis and atopic dermatitis. Provectus conducts clinical trials, expanded access programs, and non-clinical research.
The company operates across multiple international locations, conducting clinical trials and research studies at medical sites in Australia, Europe, and the United States. Its intellectual property portfolio includes patents granted across jurisdictions such as the United States, Canada, Australia, and Korea. Provectus Biopharmaceuticals maintains its principal executive offices in Knoxville, Tennessee.
Summary of the business section of Provectus Biopharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PROVECTUS BIOPHARMACEUTICALS, INC.
- Headquarters
- Knoxville, TN
- Address
- 800 S. Gay Street, Suite 1610 37929
- Phone
- (866) 594-5999
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, Los Angeles, CA
Stock & identifiers
- Ticker
- PVCT
- Exchange
- OTC
- Shares outstanding
- 420M, Aug 11, 2026
- Public float
- $30.59M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-300 reverse, Apr 11, 2002; 1-for-5000 reverse, Jun 28, 2000
- SEC CIK
- 315545
- CUSIP
- 74373P108
- ISIN
- US74373P1084
- LEI
- 549300PIIESQMJOOJG14
- EIN
- 90-0031917
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Edward Pershing | CEO, Director | 3,532,980 |
| Dominic Rodrigues | PRESIDENT, Director | 1,201,214 |
| Eric Wachter Phd | CTO | 6,649,298 |
| Heather Raines | CFO | 1,213,153 |
| John Lacey III | Director | 200,450 |
| Webster Bailey | Director | 145,528 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dominic Rodrigues | $315.00K | $27.76K | $277.50K | $52 | – |
| FY2025 Non Peo Neo | $277.50K | $26.73K | $277.50K | $52 | – |
| FY2025 Peo | $315.00K | $27.76K | $277.50K | $52 | – |
| FY2024 Dominic Rodrigues | $1.53M | $1.53M | $1.27M | $218 | – |
| FY2024 Non Peo Neo | $1.27M | $1.28M | $1.27M | $218 | – |
| FY2024 Peo | $1.53M | $1.53M | $1.27M | $218 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We have six full-time employees who currently serve as CEO, CFO, CTO, president, senior scientist, and controller.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 16, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Apr 27, 2017 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 21, 2017 | Delisting | Notice of delisting from exchange (Form 25) |
| Mar 16, 2017 | Late filing | Notification of late filing |
| Nov 30, 2016 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 18, 2016 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 13, 2016 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Apr 29, 2016 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 16, 2016 | Late filing | Notification of late filing |
| Dec 31, 2015 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 19, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 13, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 18, 2013 | Name change | Name changed from PROVECTUS PHARMACEUTICALS INC to PROVECTUS BIOPHARMACEUTICALS, INC. |
| Mar 27, 2003 | Late filing | Notification of late filing |
| May 15, 2002 | Late filing | Notification of late filing |
| May 15, 2002 | Name change | Name changed from PROVECTUS PHARMACEUTICAL INC to PROVECTUS PHARMACEUTICALS INC |
| Apr 1, 2002 | Name change | Name changed from ZAMAGE DIGITAL IMAGING INC to PROVECTUS PHARMACEUTICAL INC |
| Apr 1, 2002 | Late filing | Notification of late filing |
| Nov 14, 2001 | Name change | Name changed from SPM GROUP INC to ZAMAGE DIGITAL IMAGING INC |
| Apr 2, 2001 | Late filing | Notification of late filing |
| May 15, 2000 | Late filing | Notification of late filing |